Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
Table 4
Proportion, phenotype, and fractions of tumor-reactive lymphocytes of large-scale expanded TIL from melanoma-invaded lymph nodes from 31 patients.
Patients
Relapsed
Number of infused TIL × 109
% CD3/CD4-positiveb
% CD3/CD8-positiveb
Ratio of CD4/CD8
% IFN--positive lymphocytesc
E1a
E2
E1
E2
E1
E2
E1
E2
E1a
E2
M88*
+
6
0.7
27
39
71
59
0.4
0.7
ND
0.4
M98*
+
33.5
21.4
85
93
14
7
6.1
13.3
NA
NA
M99
−
1.7
0.8
60
33
38
61
1.6
0.5
NA
NA
M100
+
11.6
6
94
95
5
4
18.8
23.8
NA
NA
M103*
+
7.65
27.6
43
57
66
58
0.7
1.0
NA
NA
M110
−
1.13
1.05
78
84
18
18
4.3
4.7
0.0
0.0
M113
−
10
11.2
36
75
75
28
0.5
2.7
10.3
0.8
M117
+
1.4
32
30
3
70
97
0.4
0.03
ND
2.50
M125
−
12
13.2
71
65
30
36
2.4
1.8
0.0
2.4
M126
−
10.2
10.8
55
39
40
56
1.4
0.7
NA
NA
M132
−
8.3
12.2
39
20
58
80
0.7
0.3
0.0
0.0
M134
+
13.5
9
55
62
45
38
1.2
1.6
0.7
0.0
M139*
−
12.3
13.4
53
60
42
34
1.3
1.8
NA
NA
M148
−
15.2
3.1
39
46
57
55
0.7
0.8
NA
NA
M158
−
8
10.2
30
31
70
63
0.4
0.5
0.0
0.0
M170*
+
9
0.53
30
32
67
67
0.4
0.5
1.2
ND
M171
−
10
12
48
42
52
58
0.9
0.7
0.0
0.0
M174*
+
9.5
4.7
80
70
20
30
4.0
2.3
NA
NA
M180*
+
5.5
3.5
29
19
68
80
0.4
0.2
NA
NA
M182
+
0.576
3.1
87
25
13
71
6.7
0.4
0.0
0.7
M187
+
8
10
16
24
86
76
0.2
0.3
2.9
0.4
M192
−
10
15.6
49
82
51
18
1.0
4.6
NA
NA
M193
−
12
5.2
14
27
86
73
0.2
0.4
3.5
4.0
M196*
−
8.6
14
40
22
58
74
0.7
0.3
1.0
0.0
M197*
+
14
1
48
32
52
68
0.9
0.5
2.9
0.0
M199
−
5
3.3
25
14
75
86
0.3
0.2
2.7
2.4
M204
−
9.5
16.5
92
88
8
17
11.5
5.2
0
3.4
M209*
−
6.8
6.2
63
71
36
29
1.8
2.4
NA
NA
M212
−
7.8
11
52
33
47
57
1.1
0.6
0.4
1.0
M213*
+
9.1
8.5
24
24
76
72
0.3
0.3
NA
NA
M215*
+
8.8
5.5
45
68
46
31
1.0
2.2
NA
NA
Melanoma patients bearing only one metastatic lymph node.
aE1 and E2 were TIL populations obtained and reinjected to the patient from, respectively, the first and the second ex vivo expansions.
bPercentages of CD-positive TIL were estimated by membrane labeling. Cells were analyzed on a FACScan.
cPercentages of IFN- secreting TIL were estimated by intracellular labeling. TIL were stimulated 6 h by autologous melanoma cells in presence of brefeldin A. Then, cells were fixed, permeabilized, stained for cytokine production, and analyzed on a FACSCalibur.
dRelapse of patients ((−): patients who relapsed; (+): patients who did not relapse).
